Pulsesight
  • About us
    • About us
    • Team
    • Investors
  • Technology
  • Pipeline
    • Pipeline
    • About AMD
    • PST-611
    • PST-809
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Contact

Category: In the news

A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy

Posted on January 22, 2026January 23, 2026 by edgover
A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy
Posted in In the news

Targeting Iron in Dry AMD

Posted on October 29, 2025January 15, 2026 by fowlerat
Targeting Iron in Dry AMD
Posted in In the news

Research supports that iron dysregulation may drive AMD

Posted on October 28, 2025January 15, 2026 by edgover
Research supports that iron dysregulation may drive AMD
Posted in In the news

PulseSight Therapeutics Builds Non-Viral Gene Therapy Pipeline For AMD

Posted on September 15, 2025January 15, 2026 by fowlerat
PulseSight Therapeutics Builds Non-Viral Gene Therapy Pipeline For AMD
Posted in In the news

Study Connects Iron Regulation and Vision Loss

Posted on September 4, 2025January 15, 2026 by edgover
Study Connects Iron Regulation and Vision Loss
Posted in In the news

PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025

Posted on September 4, 2025January 15, 2026 by edgover
PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025
Posted in In the news

PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025

Posted on September 4, 2025January 15, 2026 by edgover
PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025
Posted in In the news

A new treatment for dry AMD and tackling peanut allergies

Posted on August 15, 2025January 15, 2026 by fowlerat
A new treatment for dry AMD and tackling peanut allergies
Posted in In the news

PulseSight doses first subject in Phase I trial of dry AMD/GA therapy

Posted on July 8, 2025January 15, 2026 by edgover
PulseSight doses first subject in Phase I trial of dry AMD/GA therapy
Posted in In the news

PulseSight Begins Dry AMD Trial

Posted on July 7, 2025January 15, 2026 by edgover
PulseSight Begins Dry AMD Trial
Posted in In the news

Posts navigation

Older posts
Newer posts

Recent Posts

  • EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
  • PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial
  • New PST-611 Data Suggest Slower GA Progression
  • PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy
  • PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • May 2026
  • April 2026
  • January 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • January 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • April 2024
  • March 2024
  • February 2024

Categories

  • In the news
  • Press release
CONTACT US
PRIVACY POLICY
DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED